Marker Therapeutics (MRKR) investor relations material

Technology overview and differentiation

• Multi-TAA T-cell technology targets multiple tumor antigens using native T cell receptors, enabling broad recognition of tumor epitopes and engaging both CD4 and CD8 T cells.

• Unlike CAR T and bispecific antibodies, this approach is not limited to surface antigens and can target intracellular proteins, expanding the range of treatable cancers.

• The natural mechanism of action results in a favorable safety profile, with minimal cytokine release syndrome and neurotoxicity observed in clinical use.

Clinical development and pipeline

• Lead asset MT-601 is prioritized for diffuse large B-cell lymphoma (DLBCL), especially in patients relapsed after CAR T and bispecific therapies, addressing a high unmet need.

• MT-601 is also being advanced into solid tumors, leveraging its broad target profile and shared development experience.

• An off-the-shelf program is planned, with first patient dosing expected in the second half of the year, aiming for rapid and simple patient access.

Clinical trial results and safety

• Phase 1 Apollo trial completed dose escalation (100–400 million cells), showing all doses were well tolerated and safe, with a clear efficacy signal.

• In 12 non-Hodgkin lymphoma patients, a 50% complete response rate and 66% overall response rate were observed, including strong responses in heavily pretreated DLBCL patients.

• Even at the highest dose, safety remains excellent, with only mild, transient cytokine release syndrome and no neurotoxicity.